Fulcrum Therapeutics & Slate Medicines Merge for Next-Generation Migraine Therapies

Fulcrum Therapeutics and Slate Medicines are coming together to develop cutting-edge treatments for migraine and other headache disorders. The combined company will operate under the Slate Medicines name and will trade on the Nasdaq under the ticker symbol SLTE. Slate Medicines successfully raised an oversubscribed $245 million private placement led by Frazier Life Sciences, along with other investors such as Forbion, RA Capital Management, and Deep Track Capital.

With a substantial cash balance, the newly formed company anticipates being able to fund operations until 2029. Migraine is a widespread and debilitating neurological condition that continues to lack effective treatments for many patients, according to Slate Medicines CEO Gregory Oakes. The merger aims to provide the necessary resources to advance SLTE-1009 and other pipeline candidates through significant clinical milestones.